Thursday - Chemical & Engineering News - American Chemical ...

18 INFORMEX Show Daily | Thursday February 21 2013 | Anaheim Convention Center Anaheim California
DFI Pharma to Represent CU in North America Region
CU Chemie
Uetikon, a
custom research
and manufacturer
of Active
Pharmaceutical
Ingredients (NCEs
and Generic
Drugs), has
appointed DFI
Pharma, as
representative of
Chemie Uetikon’s
business in North America. The change became effective last summer.
DFI Pharma will represent CU for specialty fine chemicals, pharmaceutical
intermediates, contract research—custom synthesis with supporting development;
and custom manufacturing of new chemical entities.
For more than 14 years, Faghani served Chemie Uetikon as a director of North
America region. He will now continue his co-operation with CU as an independent
representative and authorized distributor in the same region.
Registered in April 2012, David Faghani Inc. is a legal entity, a New Jersey corporation
with a principal place of business at 65 Richmond Drive, Skillman, NJ 08558.
CU’s new representative office is a milestone in the company’s strategy to affirm
its commitment to fine chemicals and pharmaceutical markets and to provide better
service and support to all CU’s customers, agents and distributors.
DFI Pharma will offer customers options to choose how they wish to be served.
The main focus will be to provide direct commercial support to CU’s customers
in collaboration with CU’s agents and distributors and to develop new business
opportunities in the America market.
DFI Pharma offers many services to exclusive principal
David Faghani Incorporated (DFI Pharma), a privately held multi-national sourcing and
supplier of pharmaceutical ingredients, specializes in sales, marketing, distribution, and
commercial development (market segments & research analysis) for high quality products
and services offered by its exclusive principal.
Their products and services include: specialty fine chemicals; GMP
pharmaceutical intermediates; advanced intermediates; contract research—
custom synthesis with supporting development, analytics, quality and regulatory
documentations; APIs (NCEs) manufactured under full cGMP—contract
development and manufacturing of new chemical entities and niche generic
representing an increasing part of our business; new developmental of generic APIs
manufactured under full cGMP; and out-licensing of new generic APIs through a
network of pharmaceutical drug manufacturers having a strong compliance system
in place, as well as, meeting all regulatory requirements.
With 30 years of experience serving the specialty chemical and pharmaceutical
markets, from early stage development to commercial, DFI Pharma has gained
an understanding of its sectors while creating strong and long-term business
partnerships. Intellectual properties rights will remain a fundamental factor in the
development of NCEs or new generic drugs.
DFI Pharma actively promotes and defends the right of its clients and principal
partners with regard to patent and regulatory issues.
Visit Chemie Uetikon and DFI Pharma at Booth 1545.